Nature, Published online: 11 March 2026; doi:10.1038/d41586-026-00715-5

A phase II trial shows that the risk of cancer recurrence as reflected by circulating tumour DNA can guide a risk-adaptive treatment strategy that improves participants’ survival compared with the current standard of care. Our biological insights can be translated into clinical decision-making — challenging the conventional fixed-course, therapeutic approach.